Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A phase I study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). Diefenbach, C., Li, H., Kahl, B. S., Robertson, M. J., Cohen, J., Advani, R. H., Ambinder, R., Fenske, T. S., Ansell, S. AMER SOC CLINICAL ONCOLOGY. 2015
View details for Web of Science ID 000358036904864